top of page



April 18, 2023

Gilboa Therapeutics Publishes and Presents Data at AACR Supporting SolidT Engineered T-Cell Platform Targeting Solid Tumors

Gilboa will present in vitro and in vivo data at the AACR Annual Meeting demonstrating

non-clinical proof of concept for SolidT cells coadministered with therapeutic antibodies.

Cambridge, MA - April 18, 2023 - Gilboa Therapeutics, a preclinical stage biotechnology company, today announced the publication of a scientific paper demonstrating that its novel T-cell therapy platform, SolidT, has the potential to reprogram T cells to detect and destroy solid tumor cells while leaving normal cells unharmed. The paper was published in Cancer Immunology Research, a journal of the American Association for Cancer Research (AACR).


The company will be presenting its data in a poster at the AACR Annual Meeting on April 18 at 9AM ET in Section 22.


Click here to read more.

Read the full article here.

Screenshot 2023-04-18 140857.png

November 2, 2023

Gilboa Therapeutics Publishes Data in the Blood Journal Supplement of ASH 2023

Gilboa publishes it groundbreaking work on SolidT, a novel engineered cytotoxic T cells therpy, in the Blood journal supplement of ASH 2023.

SolidT exhibits increased specificity, reduced exhaustion, and controlled cytokine secretion, making it a promising advancement in the treatment of lymphoma. In a CD20+ Raji-Luc xenograft model, SolidT + rituximab demonstrated superior anti-tumor activity and prolonged survival compared to traditional treatments.

Read more here.


December 19, 2022

Gilboa Therapeutics has been recognized as one of the 33 healthcare and biotech start-ups investors expect to take off in 2023

Gilboa Therapeutics has been recognized by Insider Business as one of the 33 healthcare and biotech start-ups investors expect to take off in 2023. We are grateful for the support of our investors and look forward to continuing to make progress in the development of our SolidT therapy.
We can't wait to see what the future holds for Gilboa Therapeutics!

Read the full article here.


Gilboa Therapeutics is delighted to welcome Barry Labinger as CEO

Barry Labinger brings more than 30 years of experience in leadership roles in the biopharmaceutical industry, including both public and private companies. 

We look forward to a successful journey together!

Read more about Barry here

June 15, 2022

bottom of page